standard CHOP

DRUG2 trials

Sponsors

Japan Clinical Oncology Group, Ruijin Hospital

Conditions

Non-Hodgkin's LymphomaPeripheral T Cell Lymphoma

Phase 1

Genotype-guided Treatment in Newly Diagnosed PTCL

RecruitingNCT05675813

Ruijin HospitalPeripheral T Cell Lymphoma

Start: 2023-02-13End: 2028-07-15Target: 264Updated: 2024-01-08

Phase 3

Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)

TerminatedNCT00133302

Japan Clinical Oncology GroupNon-Hodgkin's Lymphoma

Start: 1999-02-28End: 2005-02-28Target: 450Updated: 2007-01-18

Related Papers

Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial.

2024-07-293 citations